Clinical trial
A Phase I/II Study of Bexarotene in Combination With ZD1839 (IRESSA®) in the…
NCT00238628 · Stanford University, Other · Completed
Key facts
| NCT number | NCT00238628 |
|---|---|
| Title | A Phase I/II Study of Bexarotene in Combination With ZD1839 (IRESSA®) in the Treatment of Non-Small Cell Lung Cancer |
| Official title | A Phase I/II Study of Bexarotene in Combination With ZD 1839 (IRESSA) in the Third Line Treatment of Non-Small Cell Lung Cancer (NSCLC) |
| Lead sponsor | Stanford University, Other |
| Collaborators | Ligand Pharmaceuticals Industry AstraZeneca |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Lung Cancer |
| Intervention type | Drug |
| Interventions | Bexarotene, Iressa |
| Enrollment | 12 |
| Start date | Apr 1, 2004 |
| Primary completion | Apr 1, 2005 |
| Completion | Dec 1, 2005 |
| First posted | Oct 13, 2005 |
| Last update posted | Jul 20, 2010 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: